Mizuho: Healthcare Now a Value Sector as Pharma Lags Tech

Jared Holz, Mizuho's healthcare strategist, said on CNBC that healthcare has become a value sector after years of lagging the market. He argued that drug stocks are no longer just defensive holdings but could be attractive for growth-oriented investors.

Recommendation Change

Holz did not announce a specific rating change but reframed the sector from defensive to value. He suggested investors consider pharma stocks as buying opportunities after their underperformance.

Analyst's Rationale

Holz believes years of underperformance have made pharma valuations compelling. He added that the sector is less economically sensitive than previously thought, making it suitable for growth portfolios.

Context

Holz's comments come as tech stocks like NVIDIA (NVDA) outperform. In contrast, stocks like Merck (MRK) have faced regulatory and competitive pressures. Other analysts remain cautious due to regulatory uncertainty.

What to Make of It

Holz's view offers an optimistic take, but investors should weigh regulatory and competitive risks. The final decision depends on individual investment goals.